PF-06648671

PF-06648671 is a novel, brain-penetrant, and orally active small molecule γ-secretase modulator (GSM) developed for the treatment of Alzheimer's disease. Unlike γ-secretase inhibitors that block enzyme activity entirely, GSMs like PF-06648671 selectively modulate the enzyme's activity to reduce production of the more pathogenic amyloid-beta peptides Aβ42 and Aβ40 while increasing levels of shorter, less pathogenic forms such as Aβ37 and Aβ38. This mechanism aims to lower amyloidogenic risk without interfering with other essential functions of γ-secretase. Preclinical studies demonstrated potent in vitro activity (Aβ42 IC50 = 9.8 nM), favorable pharmacokinetics including good brain penetration and oral bioavailability suitable for once-daily dosing in humans. Phase I clinical trials showed robust reduction of CSF Aβ42 in healthy subjects with no significant drug-related safety concerns reported[1][3][4][6][7].